Drug exposure in pregnancy and heart defects

Journal of Cardiovascular Pharmacology

Volumn 58, Issue 1, 2011, Pages 20-24

  Matok, Ilan ^a,b   Pupco, Anna ^a,b   Koren, Gideon ^a,b  

^a Division of Clinical Pharmacology and Toxicology   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

cardiac birth defects; congenital malformations; drugs safety; pregnancy

Indexed keywords

ALCOHOL; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CITALOPRAM; COTRIMOXAZOLE; DIHYDROFOLATE REDUCTASE; FOLIC ACID; FOLIC ACID ANTAGONIST; LITHIUM; METHOTREXATE; PAROXETINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SULFAMETHOXAZOLE; SULFONAMIDE; TRIMETHOPRIM; VALPROIC ACID;

ACROCYANOSIS; ALCOHOL ABUSE; BIPOLAR DISORDER; BIRTH DEFECT; BIRTH WEIGHT; CARDIOVASCULAR RISK; CLEFT LIP PALATE; CLEFT PALATE; COGNITIVE DEFECT; CONGENITAL HEART MALFORMATION; CONGENITAL MALFORMATION; DRUG EXPOSURE; DRUG SAFETY; EBSTEIN ANOMALY; FETAL ALCOHOL SYNDROME; FETAL HYDANTOIN SYNDROME; FIRST TRIMESTER PREGNANCY; FOLATE METABOLISM; GROWTH RETARDATION; HEART ARRHYTHMIA; HEART ATRIUM SEPTUM DEFECT; HEART SEPTUM DEFECT; HEART VENTRICLE SEPTUM DEFECT; HUMAN; HYPOSPADIAS; HYPOTHYROIDISM; MUSCLE HYPOTONIA; NEPHROGENIC DIABETES INSIPIDUS; NEURAL TUBE DEFECT; POLYDACTYLY; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SPINA BIFIDA; TERATOGENESIS; TERATOGENICITY; THIRD TRIMESTER PREGNANCY; URINARY TRACT MALFORMATION;

EID: 79960435630     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31821c471b     Document Type: Review

References (71)

1. Hoffman JI. Natural history of congenital heart disease. Problems in its assessment with special reference to ventricular septal defects. Circulation. 1968;37:97-125.
2. Hoffman JI. Incidence of congenital heart disease. I. Postnatal incidence. Pediatr Cardiol. 1995;16:103-113.
3. Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol. 2002;39:1890-1900. (Pubitemid 34628268)
4. Daubeney PE, Sharland GK, Cook AC, et al. Pulmonary atresia with intact ventricular septum: impact of fetal echocardiography on incidence at birth and postnatal outcome. UK and Eire Collaborative Study of Pulmonary Atresia with Intact Ventricular Septum. Circulation. 1998;98:562-566. (Pubitemid 28371255)
5. Schoen FJ, Mitchell RN. "12. The Heart." In: Vinay K, Abbas AK, Nelson F, et al, eds. Robbins and Cotran Pathologic Basis of Disease. Philadelphia, Saunders Elsevier; 2010.
6. Moore KL. The Developing of Human: Clinically Oriented Embryology. Philadelphia, Saunders Co; 1982.
7. Mone SM, Gillman MW, Miller TL, et al. Effects of environmental exposures on the cardiovascular system: prenatal period through adolescence. Pediatrics. 2004;113:1058-1069. (Pubitemid 38437359)
8. Riaz K. Ebstein anomaly. Emedicine Web Site. Available at: http:// emedicine.medscape.com/article/154447-overview. Accessed November, 4, 2010.
9. Jones KL, Smith DW, Streissguth AP, et al. Outcome in offspring of chronic alcoholic women. Lancet. 1974;1:1076-1078.
10. Hernández-D́az S, Werler MM, Walker AM, et al. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med. 2000;343: 1608-1614. (Pubitemid 32162984)
11. Matok I, Gorodischer R, Koren G, et al. Exposure to folic acid antagonists during the first trimester of pregnancy and the risk of major malformations. Br J Clin Pharmacol. 2009;68:956-962.
12. Pedersen LH, Henriksen TB, Vestergaard M, et al. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ. 2009;339:b3569.
13. Einarson A, Pistelli A, DeSantis M, et al. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am J Psychiatry. 2008;165:749-752. (Pubitemid 351810544)
14. Schou M. What happened later to the lithium babies? A follow-up study of children bornwithoutmalformations. Acta Psychiatr Scand. 1976;54:193-197.
15. Källén B, Tandberg A. Lithium and pregnancy. A cohort study on manicdepressive women. Acta Psychiatr Scand. 1983;68:134-139. (Pubitemid 13038250)
16. Källén B. Comments on teratogen update: lithium. Teratology. 1988;38:597.
17. Cohen LS, Friedman JM, Jefferson JW, et al. A reevaluation of risk of in utero exposure to lithium. JAMA. 1994;271:146-150. (Pubitemid 24020593)
18. Jacobson SJ, Ceolin L, Kaur P, et al. Prospective multicentre study of pregnancy outcome after lithium exposure during first trimester. Lancet. 1992;339:530-533.
19. Pinelli JM, Symington AJ, Cunningham KA, et al. Case report and review of the perinatal implications of maternal lithium use. Am J Obstet Gynecol. 2002;187:245-249. (Pubitemid 34800332)
20. Giles JJ, Bannigan JG. Teratogenic and developmental effects of lithium. Curr Pharm Des. 2006;12:1531-1541. (Pubitemid 44082110)
21. Newport DJ, Viguera AC, Beach AJ, et al. Lithium placental passage and obstetrical outcome: implications for clinical management during late pregnancy. Am J Psychiatry. 200;162:2162-2170.
22. Woody JN, London WL, Wilbanks GD Jr. Lithium toxicity in a newborn. Pediatrics. 197;47:94-96.
23. Schou M, Goldfield MD, Weinstein MR, et al. Lithium and pregnancy. I. Report from the Register of Lithium Babies. BMJ. 1973;2:135-136.
24. Bonduelle M, Lormeau G. Facial painful conditions and their therapy. Therapie. 1966;21:1123-1144.
25. Karlsson K, Lindstedt G, Lundberg PA, et al. Letter: transplacental lithium poisoning: reversible inhibition of fetal thyroid. Lancet. 1975;1:1295.
26. Rane A, Tomson G, Bjarke B. Effects of maternal lithium therapy in a newborn infant. J Pediatr. 1978;93:296-297. (Pubitemid 8380053)
27. Mizrahi EM, Hobbs JF, Goldsmith DI. Nephrogenic diabetes insipidus in transplacental lithium intoxication. J Pediatr. 1979;94:493-495. (Pubitemid 9111109)
28. Morrell P, Sutherland GR, Buamah PK, et al. Lithium toxicity in a neonate. Arch Dis Child. 1983;58:539-541. (Pubitemid 13072481)
29. Mastrobattista JM, Bishop KD, Newton ER. Late diagnosis of nonconjoined monoamniotic twins using computed tomographic imaging: a case report. Obstet Gynecol. 1990;76:504-506.
30. Floyd RL, Sidhu JS. Monitoring prenatal alcohol exposure. Am J Med Genet C Semin Med Genet. 2004;127:3-9. (Pubitemid 38544023)
31. Fact Sheet: Drinking and Alcohol. Drinking Facts Site. Available at: http:// www.drinkingfacts.ca/english/downloads/facts.pdf. Accessed February 22, 2011.
32. Centers for Disease Control-Alcohol and Public Health. Available at http://www.cdc.gov/alcohol/faqs.htm#standDrink. Accessed February 22, 2011.
33. Abel EL. Fetal Alcohol Abuse Syndrome. New York, NY: Plenum Press; 1998.
34. Sampson PD, Streissguth AP, Bookstein FL, et al. Incidence of fetal alcohol syndrome and prevalence of alcohol-related neurodevelopmental disorder. Teratology. 1997;56:317-326. (Pubitemid 28035178)
35. Jones KL, Smith DW, Ulleland CN, et al. Pattern of malformation in offspring of chronic alcoholic mothers. Lancet. 1973;1:1267-1271.
36. Rosett HL, Ouellette EM, Weiner L, et al. Therapy of heavy drinking during pregnancy. Obstet Gynecol. 1978;51:41-46. (Pubitemid 8282084)
37. Carmichael SL, Shaw GM, Yang W, et al. Maternal periconceptional alcohol consumption and risk for conotruncal heart defects. Birth Defects Res Part A Clin Mol Teratol. 2003;67:875-878. (Pubitemid 37337570)
38. Burd L, Deal E, Rios R, et al. Congenital heart defects and fetal alcohol spectrum disorders. Congenit Heart Dis. 2007;2:250-255. (Pubitemid 47161797)
39. Jones KL, Smith DW, Streissguth AP, et al. Outcome in offspring of chronic alcoholic women. Lancet. 1974;1:1076-1078.
40. Kvigne VL, Leonardson GR, Neff-Smith M, et al. Characteristics of children who have full or incomplete fetal alcohol syndrome. J Pediatr. 2004;145:635-640. (Pubitemid 39440942)
41. Czeizel AE. Periconceptional folic acid containing multivitamin supplementation. Eur J Obstet Gynecol Reprod Biol. 1998;78:151-161. (Pubitemid 28201105)
42. Botto LD, Khoury MJ, Mulinare J, et al. Periconceptional multivitamin use and the occurrence of conotruncal heart defects: results from a population-based, case-control study. Pediatrics. 1996;98:911-917. (Pubitemid 26398775)
43. Botto LD, Mulinare J, Erickson JD. Occurrence of congenital heart defects in relation to maternal multivitamin use. Am J Epidemiol. 2000;151: 878-884. (Pubitemid 30461128)
44. Matok I, Levy A, Gorodischer R, et al. Fetal risk versus safety of medications in pregnancy: epidemiologic considerations.In: Sheiner E. Textbook of Perinatal Epidemiology. Hauppauge, Nova Publishers, 2010.
45. Feldkamp M, Carey JC. Clinical teratology counseling and consultation case report: low dose methotrexate exposure in the early weeks of pregnancy. Teratology. 1993;47:533-539. (Pubitemid 23172495)
46. Kozlowski RD, Steinbrunner JV, MacKenzie AH, et al. Outcome of firsttrimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am J Med. 1990;88:589-592. (Pubitemid 20192270)
47. Lewden B, Vial T, Elefant E, et al. Low dose methotrexate in the first trimester of pregnancy: results of a French collaborative study. J Rheumatol. 2004;31:2360-2365. (Pubitemid 39603082)
48. Krähenmann F, OStensen M, Stallmach T, et al. In utero first trimester exposure to low-dose methotrexate with increased fetal nuchal translucency and associated malformations. Prenat Diagn. 2002;22:489-490. (Pubitemid 34716940)
49. Nguyen C, Duhl AJ, Escallon CS, et al. Multiple anomalies in a fetus exposed to low-dose methotrexate in the first trimester. Obstet Gynecol. 2002;99:599-602. (Pubitemid 34246297)
50. Czeizel AE, Rockenbauer M, SÃÂ̧rensen HT, et al. The teratogenic risk of trimethoprim-sulfonamides: a population based case-control study. Reprod Toxicol. 2001;15:637-646. (Pubitemid 34000933)
51. Arpino C, Brescianini S, Robert E, et al. Teratogenic effects of antiepileptic drugs: use of an International Database on Malformations and Drug Exposure (MADRE). Epilepsia. 2000;41:1436-1443.
52. Meadow SR. Anticonvulsant drugs and congenital abnormalities. Lancet. 1968;2:1296.
53. Loughnan PM, Gold H, Vance JC. Phenytoin teratogenicity in man. Lancet. 1973;1:70-72.
54. Hill RM, Horning MG, Horning EC. Antiepileptic drugs and fetal wellbeing. In: Boreus L, ed. Fetal Pharmacology. New York, NY: Raven Press; 1973:375-379.
55. Phenytoin. In: Brigs GG, Freeman RK, Yaffe SJ, eds. A Reference Guide to Fetal and Neonatal Risk. Drugs in Pregnancy and Lactation. Philadelphia, PA. Lippincott Williams & Wilkins 2008 1476-1487.
56. Speidel BD, Meadow SR. Maternal epilepsy and abnormalities of the fetus and newborn. Lancet. 1972;7782:839-843.
57. Harden CL, Meador KJ, Pennell PB, et al. Management issues for women with epilepsy-focus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes: report of the quality standards subcommittee and therapeutics and technology subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia. 2009;50:1237-1246.
58. Jentink J, LoaneMA, Dolk H, et al. Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl J Med. 2010;362:2185-2193.
59. Delgado-Escueta AV, Janz D. Consensus guidelines: preconception counseling, management, and care of the pregnant woman with epilepsy. Neurology. 1992; 42:149-160.
60. Matalon S, Schechtman S, Goldzweig G, et al. The teratogenic effect of carbamazepine: a meta-analysis of 1255 exposures. Reprod Toxicol. 200; 16:9-17.
61. Eadie MJ. Antiepileptic drugs as human teratogens. Expert Opin Drug Saf. 2008;7:195-209. (Pubitemid 351447702)
62. Harden CL, Sethi NK. Epileptic disorders in pregnancy: an overview. Curr Opin Obstet Gynecol. 2008;20:557-562.
63. Einarson TR, Einarson A. Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiol Drug Saf. 2005;14:823-827. (Pubitemid 43056107)
64. Wen SW, Yang Q, Garner P, et al. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol. 2006;194:961-966.
65. Malm H, Klaukka T, Neuvonen PJ. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol. 2005;106:1289-1296. (Pubitemid 41668948)
66. Cole JA, Ephross SA, Cosmatos IS, et al. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf. 2007;16:1075-1085. (Pubitemid 350020060)
67. Källén B, Otterblad Olausson P. Antidepressant drugs during pregnancy and infant congenital heart defect. Reprod Toxicol. 2006;21:221-222. (Pubitemid 43294548)
68. Oââ,â.,¢Brien L, Einarson TR, Sarkar M, et al. Does paroxetine cause cardiac malformations? J Obstet Gynaecol Can. 2008;30:696-701.
69. Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation. Philadelphia, PA: Lippincott Williams & Wilkins; 2008.
70. Bar-Oz B, Einarson T, Einarson A, et al. Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors. Clin Ther 2007;29:918-926. (Pubitemid 47223423)
71. Du ZD, Roguin N, Barak M, et al. High prevalence of muscular ventricular septal defect in preterm neonates. Am J Cardiol. 1996;78:1183-1185. (Pubitemid 126657190)